Lumos Total Assets from 2010 to 2024
| LUMO Stock | USD 4.30 0.02 0.46% |
Total Assets | First Reported 2009-12-31 | Previous Quarter 21.4 M | Current Value 17.5 M | Quarterly Volatility 66.3 M |
Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.
Lumos | Total Assets |
Latest Lumos Pharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of Lumos Pharma over the last few years. Total assets refers to the total amount of Lumos Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lumos Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Lumos Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 40.64 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Lumos Total Assets Regression Statistics
| Arithmetic Mean | 105,306,407 | |
| Geometric Mean | 79,573,145 | |
| Coefficient Of Variation | 67.71 | |
| Mean Deviation | 58,690,875 | |
| Median | 96,787,000 | |
| Standard Deviation | 71,299,147 | |
| Sample Variance | 5083.6T | |
| Range | 227.5M | |
| R-Value | (0.03) | |
| Mean Square Error | 5469.9T | |
| R-Squared | 0.0009 | |
| Significance | 0.92 | |
| Slope | (468,948) | |
| Total Sum of Squares | 71170T |
Lumos Total Assets History
Other Fundumenentals of Lumos Pharma
Lumos Pharma Total Assets component correlations
Click cells to compare fundamentals
About Lumos Pharma Financial Statements
Lumos Pharma investors utilize fundamental indicators, such as Total Assets, to predict how Lumos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 40.6 M | 38.6 M |
Check out the analysis of Lumos Pharma Correlation against competitors. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.